A single weekly dose of imatinib is sufficient to induce and maintain remission of chronic eosinophilic leukaemia in FIP1L1-PDGFRA-expressing patients

British Journal of Haematology

Volumn 141, Issue 2, 2008, Pages 200-204

  Helbig, Grzegorz ^a   Stella Hołowiecka, Beata ^a   Majewski, Mirosław ^b   Całbecka, Małgorzata ^c   Gajkowska, Jolanta ^c   Klimkiewicz, Ryszard ^d   Moskwa, Andrzej ^c   Grzegorczyk, Janina ^e   Lewandowska, Monika ^b   Hołowiecki, Jerzy ^a  

^a MEDICAL UNIVERSITY OF SILESIA   (Poland)

^b INSTITUTE OF HEMATOLOGY AND TRANSFUSION MEDICINE   (Poland)

^c Provincial Hospital   (Poland)

^d Provincial Hospital   (Poland)

^e MEDICAL UNIVERSITY OF LODZ   (Poland)

Author keywords

Chronic eosinophilic leukaemia; FIP1L1 PDGFRA; Hypereosinophilic syndrome; Imatinib; Maintenance

Indexed keywords

IMATINIB; PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR; PROTEIN; PROTEIN FIP1L1; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CANCER CHEMOTHERAPY; CANCER REGRESSION; CHROMOSOME DELETION 4; CHRONIC EOSINOPHILIC LEUKEMIA; CLINICAL ARTICLE; DOSE RESPONSE; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; EOSINOPHILIC LEUKEMIA; FEMALE; FUSION GENE; GENE EXPRESSION; GENE EXPRESSION PROFILING; HUMAN; HYPEREOSINOPHILIC SYNDROME; MAINTENANCE THERAPY; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SINGLE DRUG DOSE; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; CHRONIC DISEASE; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYPEREOSINOPHILIC SYNDROME; MALE; MIDDLE AGED; MRNA CLEAVAGE AND POLYADENYLATION FACTORS; ONCOGENE PROTEINS, FUSION; PIPERAZINES; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES; PYRIMIDINES; RECEPTOR, PLATELET-DERIVED GROWTH FACTOR ALPHA; REMISSION INDUCTION; TREATMENT OUTCOME;

EID: 40949147830     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/j.1365-2141.2008.07033.x     Document Type: Article

References (16)

1. Baccarani, M., Cilloni, D., Rondoni, M., Ottaviani, E., Messa, F., Merante, S., Tribelli, M., Buccisano, F., Testoni, N., Gottardi, E., de Vivo, A., Giugliano, E., Iacobucci, I., Paolini, S., Soverini, S., Rosti, G., Rancati, F., Astolfi, C., Pane, F., Saglio, F. Martinelli, G. (2007) The efficacy of imatinib mesylate in patients with FIP1L1-PDGFRα positive hypereosinophilic syndrome. Results of a multicenter prospective study. Haematologica, 92, 1173 1179.
2. Chusid, M.J., Dale, D.C., West, B.C. Wolff, S.M. (1975) The hypereosinophilic syndrome: analysis of fourteen cases with review of the literature. Medicine, 54, 1 27.
3. Cools, J., De Angelo, D.J., Gotlib, J., Stover, E.H., Legare, R.D., Cortes, J., Kutok, J., Clark, J., Galinsky, I., Griffin, J.D., Cross, N.C., Tefferi, A., Malone, J., Alam, R., Schrier, S.L., Schmid, J., Rose, M., Vandenberghe, P., Verhoef, G., Boogaerts, M., Wlodarska, I., Kantarjian, H., Marynen, P., Coutre, S.E., Stone, R. Gilliliand, D.G. (2003) A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. New England Journal of Medicine, 348, 1201 1214.
4. Curtis, C.E., Grand, F.H., Musto, P., Clark, A., Murphy, J., Perla, G., Minervini, M.M., Stewart, J., Reiter, A. Cross, N.C.P. (2007) Two novel imatinib-responsive PDGFRA fusion genes in chronic eosinophilic leukaemia. British Journal of Haematology, 138, 77 81.
5. Helbig, G., Stella-Holowiecka, B., Grosicki, S., Bober, G., Krawczyk, M., Wojnar, J., Reiter, A., Hochhaus, A. Holowiecki, J. (2006) The results of imatinib therapy for patients with primary eosinophilic disorders. European Journal of Haematology, 76, 535 536.
6. Jovanovic, J., Score, J., Waghorn, K., Cilloni, D., Gottardi, E., Metzgeroth, G., Erben, P., Popp, H., Walz, C., Hochhaus, A., Roche-Lestienne, C., Preudhomme, C., Solomon, E., Apperley, J., Rondoni, M., Ottaviani, E., Martinelli, G., Brito-Babapulle, F., Saglio, G., Hellmann, R., Cross, N.C.P., Reiter, A. Grimwade, D. (2007) Low-dose imatinib mesylate leads to rapid induction of major molecular response and achievement of complete molecular remission in FIP1L1-PDGFRA positive chronic eosinophilic leukemia. Blood, 109, 4635 4641.
7. Kerkela, R., Grazette, L., Yacobi, R., Iliescu, C., Patten, R., Beahm, C., Walters, B., Shevtsov, S., Pesant, S., Clubb, F.J., Rosenzweig, A., Salomon, R.N., van Etten, R.A., Alroy, J., Durand, J.B. Force, T. (2007) Cardiotoxicity of the cancer therapeutic agent imatinib mesylate. Nature Medicine, 12, 908 916.
8. Klion, A.D., Noel, P., Akin, C., Law, M.A., Gilliliand, G., Cools, J., Metcalfe, D.D. Nutman, T.B. (2003) Elevated serum tryptase levels identify a subset of patients wit a myeloproliferative variant of idiopathic hypereosinophilic syndrome associated with tissue fibrosis, poor prognosis and imatinib responsiveness. Blood, 101, 4660 4666.
9. Klion, A.D., Robyn, J., Akin, C., Noel, P., Brown, M., Law, M., Metcalfe, D.D., Dunbar, C. Nutman, T.B. (2004) Molecular remission and reversal of myelofibrosis in response to imatinib mesylate treatment in patients with the myeloproliferative variant of hypereosinophilic syndrome. Blood, 103, 473 478.
10. Klion, A.D., Robyn, J., Maric, I., Fu, W., Schmid, L., Lemery, S., Noel, P., Law, M.A., Hartsell, M., Talar-Williams, C., Fay, M.P., Dunbar, C.E. Nutman, T.B. (2007). Relapse following discontinuation of imatinib mesylate therapy for FIP1L1/PDGFRA-positive chronic eosinophilic leukemia: implications for optimal dosing. Blood, 110, 3352 3556.
11. La Starza, R., Specchia, G., Cuneo, A., Beacci, D., Nozzoli, C., Luciano, L., Aventin, A., Sambani, C., Testoni, N., Foppoli, M., Invernizzi, R., Marynen, P., Martelli, M.F. Mecucci, C. (2005) The hypereosinophilic syndrome: fluorescence in situ hybridization detects the del (4)(q12)-FIP1L1-PDGFRA but not genomic rearrangements of other tyrosine kinases. Haematologica, 90, 596 601.
12. Muller, A.M., Martens, U.M., Hofmann, S.C., Bruckner-Tuderman, L., Mertelsmann, R. Lubbert, M. (2006) Imatinib mesylate as a novel treatment option for hypereosinophilic syndrome: two case reports and a comprehensive review of the literature. Annals of Hematology, 85, 1 16.
13. Pardanani, A., Brockman, S.R., Patemoster, S.F., Flynn, H.C., Ketterling, R.P., Lasho, T.L., Ho, C.L., Li, C.Y., Dewald, G.W. Tefferi, A. (2004) FIP1L1-PDGFRA fusion: prevalence and clinicopathologic correlates in 89 conscutive patients with moderate to severe eosinophilia. Blood, 104, 3038 3045.
14. Pardanani, A., Ketterling, R.P., Li, C.Y., Patnaik, M.M., Wolanskyj, A.P., Elliot, M.A., Camoriano, J.K., Butterfield, J.H., Ewald, G.W. Tefferi, A. (2006) FIP1L1-PDGFRA in eosinophilic disorders: Prevalence in routine clinical practice, long-term experience with imatinib therapy, and a critical review of the literature. Leukemia Research, 30, 965 970.
15. Roche -Lestienne, C., Lepers, S., Soenen-Cornu, V., Kahn, J.E., Lai, J.L., Hachulla, E., Drupt, F., Demarty, A.L., Roumier, A.S., Gardembas, M., Dib, M., Philippe, N., Cambier, N., Barete, S., Libersa, C., Bletry, O., Hatron, P.Y., Quesnel, B., Rose, C., Maloum, K., Blanchet, O., Fenaux, P., Prin, L. Preudhomme, C. (2005) Molecular characterization of the idiopathic hypereosinophilic syndorme (HES) in 35 French patients with normal conventional cytogenetics. Leukemia, 19, 792 798.
16. Vandenberghe, P., Wlodarska, I., Michaux, L., Zachee, P., Boogaerts, M., Vanstraelen, D., Herregods, M.C., Van Hoof, A., Selleslag, D., Roufosse, F., Maerevoet, M., Verhoef, G., Cools, J., Gilliliand, D.G., Hagemeijer, A. Marynen, P. (2004) Clinical and molecular features of FIP1L1-PDGFRA (+) chronic eosinophilic leukemia. Leukemia, 18, 734 742.